- Trastuzumab deruxtecan in the treatment of patients with metastatic HER2‑low breast cancer2023 | First Faculty of Medicine
- Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group2023 | Faculty of Medicine in Pilsen
- Treatment of HER2-positive breast cancer in 20202020 | First Faculty of Medicine
- Standing ovations jsou zasloužené2023 | First Faculty of Medicine
- Prediktivní biomarkery u karcinomu prsu - současný stav a výhled do (bližší i vzdálenější) budoucnosti2022 | Faculty of Medicine in Hradec Králové
- HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Second Faculty of Medicine
- Aktuální možnosti léčby metastazujícího triple negativního karcinomu prsu2022 | First Faculty of Medicine
